Functional Imaging of Lung Cancer Using Dual Energy CT: How Does Iodine Related Attenuation Correlate with Standardized Uptake Value of 18FDG-PET-CT?
Overview
Authors
Affiliations
Objectives: To investigate the correlation between maximum standardized uptake value (SUV(max)) of (18)FDG PET-CT and iodine-related attenuation (IRA) of dual energy CT (DECT) of primary tumours and (18)FDG PET-CT positive thoracic lymph nodes (LN) in patients with lung cancer.
Methods: 37 patients with lung cancer (27 NSCLC, 10 SCLC, 86 (18)FDG PET-CT positive thoracic LN) who underwent both (18)FDG PET-CT and DECT were analyzed. The mean study interval between (18)FDG PET-CT and DECT was ≤21 days in 17 patients. The mean and maximum IRA of DECT as well as of virtual unenhanced and virtual 120 kV images of DECT was analyzed and correlated to the SUV(max) of (18)FDG PET-CT in all tumours and (18)FDG PET-CT positive thoracic lymph nodes. Further subgroup analysis was performed for histological subtypes in all groups.
Results: A moderate correlation was found between SUV(max) and maximum IRA in all tumours (n = 37;r = 0.507;p = 0.025) whereas only weak or no correlation were found between SUV(max) and all other DECT measurements. A strong correlation was found in patients with study intervals ≤21 days (n = 17; r = 0.768;p = 0.017). Analysis of histological subtypes of lung cancer showed a strong correlation between SUV(max) and maximum IRA in the analysis of all patients with NSCLC (r = 0.785;p = 0.001) and in patients with NSCLC and study intervals ≤21 days (r = 0.876;p = 0.024). Thoracic LN showed moderate correlation between SUV(max) and maximum IRA in patients with study intervals ≤21 days (r = 0.654; p = 0.010) whereas a weak correlation was found between SUV(max) and maximum IRA in patients with study intervals >21 days (r = 0.299; p = 0.035).
Conclusions: DECT could serve as a valuable functional imaging test for patients with NSCLC as the IRA of DECT correlates with SUV(max) of (18)FDG PET-CT.
Dual-energy CT in head and neck applications.
Tunlayadechanont P, Sananmuang T Neuroradiol J. 2025; 19714009251313507.
PMID: 39773001 PMC: 11713968. DOI: 10.1177/19714009251313507.
Zhan Y, Wang Y, Wang P, Wang Y, Ni X, Wang J Eur Radiol. 2023; 33(12):9052-9062.
PMID: 37405505 DOI: 10.1007/s00330-023-09837-0.
State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer.
Yao Y, Fareed R, Zafar A, Saleem K, Huang T, Duan Y Front Oncol. 2022; 12:958505.
PMID: 35978836 PMC: 9376330. DOI: 10.3389/fonc.2022.958505.
Brun Andersen M, Drljevic-Nielsen A, Thygesen J, Kruis M, Hjorthaug K, Rasmussen F Tomography. 2022; 8(4):1770-1780.
PMID: 35894014 PMC: 9326656. DOI: 10.3390/tomography8040149.
Brendlin A, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T J Immunother Cancer. 2021; 9(11).
PMID: 34795006 PMC: 8603266. DOI: 10.1136/jitc-2021-003261.